IDEAYA Reports 17.4-Month Median Survival With IDE849 in Second-Line Small Cell Lung Cancer Trial

• IDEAYA Biosciences announced updated Phase 1 results showing tumor responses and encouraging preliminary survival outcomes for IDE849 in relapsed lung and neuroendocrine cancers.
• Partner Hengrui will present the results at ESMO on October 26, 2026, following longer follow-up than previously reported.
• Severe treatment-related side effects were mainly blood-related; treatment discontinuations were uncommon, with one treatment-related death reported.
• Two randomized global Phase 3 trials are planned in previously treated extensive-stage small cell lung cancer and neuroendocrine carcinomas.
• A separate global Phase 1/2 trial update is targeted for late 2026 or early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610230600PR_NEWS_USPR_____SF78436) on October 23, 2026, and is solely responsible for the information contained therein.